Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- PCR Oncology — Arroyo Grande, California
- Sutter Auburn Faith Hospital — Auburn, California
- Sutter Cancer Centers Radiation Oncology Services-Auburn — Auburn, California
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04402788
Sites in California: - UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- Palo Alto Medical Foundation Health Care — Palo Alto, California
- Sutter Cancer Centers Radiation Oncology Services-Roseville — Roseville, California
- Sutter Medical Center Sacramento — Sacramento, California
Phase 3 Recruiting Academic/Other
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632327
Sites in California: - Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- Enloe Medical Center — Chico, California
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in California: - Tower Cancer Research Foundation — Beverly Hills, California
- Veterans Affairs Loma Linda Healthcare System — Loma Linda, California
- Cedars Sinai Medical Center — Los Angeles, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- Torrance Memorial Physician Network - Cancer Care — Torrance, California
Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- PCR Oncology — Arroyo Grande, California
- Kaiser Permanente-Bellflower — Bellflower, California
- Kaiser Permanente Downey Medical Center — Downey, California
- Kaiser Permanente-Fontana — Fontana, California
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in California: - Providence Medical Foundation — Fullerton, California
- Providence St. Jude Medical Center — Fullerton, California
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in California: - Clinical Study Site — Cerritos, California
- Clinical Study Site — Glendale, California
- Clinical Study Site — Irvine, California
- Clinical Study Site — Los Angeles, California
- Clinical Study Site — Mountain View, California
Phase 3 Recruiting Industry
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…
Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in California: - UCLA Hematology/Oncology - Santa Monica — Los Angeles, California
- Profound Research LLC — Oceanside, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center — Orange, California
- Stanford Cancer Center — Palo Alto, California
- Kaiser Permanente San Diego Mission Road — San Diego, California
Phase 3 Recruiting Industry
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary en…
Sponsor: Summit Therapeutics
NCT ID: NCT05899608
Sites in California: - LA Cancer Network — Anaheim, California
- The Oncology Institute of Hope & Innovation — Cerritos, California
- University of Southern California (USC) — Los Angeles, California
- Cedar Sinai Medical Center — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in California: - UC San Diego Health System - Encinitas — Encinitas, California
- UC San Diego Moores Cancer Center — La Jolla, California
- UC San Diego Medical Center - Hillcrest — San Diego, California
- California Protons Cancer Therapy Center — San Diego, California
Phase 3 Recruiting Industry
TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable gen…
Sponsor: AstraZeneca
NCT ID: NCT07291037
Sites in California: - Research Site — Duarte, California
- Research Site — Irvine, California
- Research Site — La Jolla, California
- Research Site — Loma Linda, California
- Research Site — Los Angeles, California
Phase 3 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…
Sponsor: AbbVie
NCT ID: NCT04928846
Sites in California: - City of Hope /ID# 243157 — Duarte, California
- City Of Hope - Seacliff /ID# 263143 — Huntington Beach, California
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 263144 — Irvine, California
- City Of Hope - Antelope Valley /ID# 263138 — Lancaster, California
- The Oncology Institute Of Hope & Innovation -East Los A /ID# 239774 — Los Angeles, California
Phase 3 Recruiting Industry
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tir…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312137
Sites in California: - Beverly Hills Cancer Center ( Site 0070) — Beverly Hills, California
- The Angeles Clinic and Research Institute ( Site 0040) — Los Angeles, California
- The Angeles Clinic and Research Institute- A Cedars-Sinai Affiliate ( Site 0079) — Los Angeles, California
- UCLA Clinical & Translational Research Center (CTRC) ( Site 0033) — Los Angeles, California
- Hoag Memorial Hospital Presbyterian ( Site 0096) — Newport Beach, California
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in California: - Providence St. Jude Medical Center ( Site 0106) — Fullerton, California
- VA Long Beach Healthcare System ( Site 0199) — Long Beach, California
- USC Norris Comprehensive Cancer Center ( Site 0205) — Los Angeles, California
- UCSF Medical Center at Mission Bay ( Site 0178) — San Francisco, California
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in California: - Local Institution - 0581 — Fullerton, California
- Local Institution - 0682 — Loma Linda, California
- Helios Clinical Research — Long Beach, California
- Local Institution - 0623 — Santa Barbara, California
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in California: - UCSD — La Jolla, California
Phase 3 Recruiting Industry
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
Sponsor: Amgen
NCT ID: NCT07005128
Sites in California: - Translational Research in Oncology US Inc, Trio Central Pharmacy — Los Angeles, California
- University of California Los Angeles — Santa Monica, California
- Presbyterian Intercommunity Hospital Health Whitter Hospital — Whittier, California
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Sites in California: - USC/Norris Comprehensive Cancer Center — Los Angeles, California
- Local Institution - 0444 — Los Angeles, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06350097
Sites in California: - Research Site — Fountain Valley, California
- Research Site — Los Alamitos, California
- Research Site — Los Angeles, California
- Research Site — Los Angeles, California
- Research Site — Orange, California
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in California: - City of Hope Cancer Center — Duarte, California
- University of California San Diego Medical Center — La Jolla, California
- University of California Los Angeles — Los Angeles, California
- St. Joseph Hospital Center for Cancer Prevention and Treatment — Orange, California
- Stanford University Medical Center — Stanford, California
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in California: - John Muir Clinical Research Center — Concord, California
- University Of California - San Diego Moores Cancer Center — La Jolla, California
Phase 3 Recruiting Academic/Other
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation thera…
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
NCT ID: NCT06095583
Sites in California: - SCRI Nashville — Davis, California
- Zangmeister Cancer Center (Columbus, OH) — Los Angeles, California
- Los Angeles Hematology Oncology — Los Angeles, California
- University of Southern California Norris Comprehensive Cancer — Los Angeles, California
Phase 2, Phase 3 Recruiting Industry
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in California: - Local Institution - 0279 — Irvine, California
- Local Institution - 0154 — Orange, California
Phase 3 Recruiting Industry
This study is open to adults 18 years and older who have early-stage non-small cell lung cancer (NSCLC). Their cancer must have a specific change in a gene called HER2. Genes provide the instructions for making proteins, and this change le…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in California: - ClinRé 001-022 (Premier Cancer Care and Infusion Center) — Fresno, California
- OPN Healthcare, Inc. — Glendale, California
- University of California Irvine — Irvine, California
- Sutter Health — Roseville, California
- University of California San Francisco — San Francisco, California
Phase 3 Recruiting Industry
This is a randomized, open-label, phase 3 clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (experimental arm) versus docetaxel monotherapy (control arm). Enrolled participants will be randomized 2:…
Sponsor: ImmunityBio, Inc.
NCT ID: NCT06745908
Sites in California: - Chan Soon-Shiong Institute for Medicine — El Segundo, California
- MemorialCare - Orange Coast Medical Center — Fountain Valley, California
- OPN Healthcare INC — Glendale, California
- OPN Healthcare INC/ Cancer and Blood Specialty Clinic — Los Alamitos, California